search innovation
New active compound for the prevention and treatment of infections caused by Zika virus (ZIKV)
keywords: Zika virus, ZIKV, sodium polystyrene sulfonate, PSSNa, active compound, antiviral treatment
offer number: 491

Zika virus (ZIKV), a member of the Flaviviridae virus family, was isolated for the first time in 1947 from a macaque sample. For many years, however, it failed to attract special attention from scientists due to its very rare and often asymptomatic infections in humans. This began to change in 2007 when the ZIKV epidemic broke out in Micronesia. Six years later, another epidemic broke out in the region of French Polynesia, where the disease affected nearly 20,000 people. The next wave of cases occurred in Brazil and affected up to 1,300,000 people. Zika virus soon started to spread throughout the world relatively quickly, with the World Health Organisation (WHO) qualifying it as a pathogen posing an international threat to human health. Data recorded by WHO from 2019 shows that a total of 87 countries and territories have reported evidence of Zika virus transmission. With the increasing number of cases, it has been observed that the consequences of diseases can be very serious. Many serious birth defects are detected in children of women infected during pregnancy and disability, which is referred to as the congenital Zika syndrome (CZS). The most common birth defects include microcephaly, brain tissue damage, retinal scarring, macular scarring, congenital contractures such as clubfoot or arthrogryposis, as well as hypertonia limiting muscle movement after birth. In adults, a ZIKV infection is also associated with various neurological complications, such as Guillain-Barré syndrome.


Although the Zika virus poses a serious threat to health, there is currently no effective vaccine, nor a specific antiviral approved for the treatment of ZIKV infections. When infected, only supportive care can presently be instituted. Therefore, there is a need to create a new inhibitory drug which: as its active substance would contain a compound effectively terminating ZIKV virus replication; would have low toxicity; its use would decrease the risk of complications and relieve symptoms of the disease. To aid the search for the cure for the Zika virus, a new active compound which fulfils the criteria specified above is proposed.

 

Features of the invention:

  • a new inhibitor preventing Zika virus replication- sodium polystyrene sulfonate (PSSNa);
  • established mechanism of PSSNa antiviral activity;
  • antiviral activity and inhibition of Zika replication confirmed in in vitro tests;
  • very low or undetectable drug toxicity in in vitro tests;
  • possibility of use through an intravenous route of administration.

 

The offered solution is subject of a patent application. Further work in its development is carried out by scientists from the Faculty of Chemistry and the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently Centre for Technology Transfer CITTRU is looking for partners to cooperate with, to commence further commercialisation of this innovation, particularly with obtaining a wide range of licenses for the new drug described above and its application.

commercial utility: prevention and / or treatment of the infection caused by Zika virus (ZIKV)

Logotypy: Fundusze Europejskie, Rzeczpospolita Polska, Unia Europejska
field of science: biochemistry, biophysics, biology, medical biology, medicine, pharmaceutical science, health sciences, biotechnology
forms of protection: patent application
technological maturity: demanding R & D
property rights: Jagiellonian University
variants of cooperation: license, consulting, spin-off company, comercial contract research

information / broker of Jagiellonian University

name and surname: Klaudia Polakowska, PhD
phone number: +48 12 664 42 13, +48 519 329 129
NEWS
latest information
Big Pharma Day online
Big Pharma Day online is an industry meeting on the development of drug projects, organized by CTT CITTRU, happening on March 25, 2021. The event will include expert presentations and individual meetings.
A new, effective method for obtaining common ash cuttings
Discover a new technology for obtaining cuttings of common ash developed by the interdisciplinary research team from the Jagiellonian University and the University of Agriculture in Krakow.
Development of biotization technology for commercial and ecological production of berry fruits
The scientific team from Jagiellonian University developed an inoculum that stimulates seedling growth.
CITTRU team
Our employees
PARTNERS
Innovation Forum KrakówKlaster Lifescience KrakówWolves SummitPACTTJagiellońskie Centrum Innowacji
Contact
GET IN TOUCH WITH US
Centre for Technology Transfer CITTRU
Jagiellonian University in Kraków - POLAND
ul. Bobrzyńskiego 14,
30-348 Kraków

PHONE:
+48 12 664 42 00
E-MAIL:
cittru@uj.edu.pl
Fundusze EuropejskieMNiSWInkubator InnowacyjnościUnia Europejska